Article in The Journal of experimental medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
12 authors.
Jiaxi Song *State Key Laboratory of Immune Response and Immunotherapy, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China , Hefei, China.ORCID 0009-0002-0788-6206
Jiabao WangState Key Laboratory of Immune Response and Immunotherapy, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China , Hefei, China.ORCID 0009-0003-7030-0607
Xuewei QiState Key Laboratory of Immune Response and Immunotherapy, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China , Hefei, China.ORCID 0009-0004-1339-5635
Jiaxin MaState Key Laboratory of Immune Response and Immunotherapy, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China , Hefei, China.ORCID 0009-0007-2077-415X
Qing LiuState Key Laboratory of Immune Response and Immunotherapy, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China , Hefei, China.ORCID 0009-0008-5446-945X
Jing YangState Key Laboratory of Immune Response and Immunotherapy, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China , Hefei, China.ORCID 0009-0007-7109-3346
Haoyu YuState Key Laboratory of Immune Response and Immunotherapy, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China , Hefei, China.ORCID 0009-0007-5878-998X
Lilin YeInstitute of Immunological Innovation and Translation, Chongqing Medical University , Chongqing, China.ORCID 0000-0003-0778-3311
Qizhao HuangDepartment of Hepatobiliary Surgery, The First Affiliated Hospital, Institute of Immunological Innovation and Translation, Chongqing Medical University, Chongqing, China.ORCID 0000-0002-5073-311X
Jia LiState Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Joint International Research Laboratory of Respiratory Health, Guangdong Basic Research Center of Excellence for Respiratory Medicine, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University , Guangzhou, China.ORCID 0009-0009-7116-9296
Fengyin LiState Key Laboratory of Immune Response and Immunotherapy, School of Basic Medical Sciences, Division of Life Sciences and Medicine, University of Science and Technology of China , Hefei, China.ORCID 0000-0003-4881-3281
Funding
China Postdoctoral Science Foundation 2022M713051Chinese Academy of Sciences XDB0490000Guangzhou National Laboratory GZNL2023A02011Ministry of Science and Technology of China 2023YFC2306400National Natural Science Foundation of China 31801222National Natural Science Foundation of China 32070888National Natural Science Foundation of China 32200722National Natural Science Foundation of China 82022031National Natural Science Foundation of China 82322031National Natural Science Foundation of China 82370148Natural Science Foundation of Chongqing CSTB2023NSCQ-LZX0010Natural Science Foundation of Chongqing CSTB2024NSCQ-JQX0008University of Science and Technology of China WK9100000020University of Science and Technology of China WK9100000039
6 · The paper itself
Abstract
CD8+ T cell exhaustion represents a major obstacle to effective cancer immunotherapy. While stem-like progenitor exhausted T (TPEX) cells can differentiate into intermediate (Int-TEX) and terminally exhausted (TEX) subsets, the epigenetic regulation of this process is unclear. We identify the RNA methyltransferase Mettl8 as a critical regulator, with expression significantly higher in TPEX than in TEX subsets. In anti-PD-1 responding non-small cell lung cancer patients, Mettl8 and the stemness factor TCF7 were downregulated. In murine models, Mettl8 deletion restrained tumor progression by driving TPEX differentiation into effective Int-TEX cells. Mechanistically, Mettl8 stabilizes Tcf7 mRNA via m3C modification and enhances Tcf1 protein expression. Additionally, Mettl8 interacts with Tcf1 to facilitate chromatin looping at the Tox locus, maintaining TPEX stemness. Pharmacological Mettl8 inhibition promoted TPEX-to-Int-TEX differentiation and tumor control. Combining this inhibition with anti-PD-1 therapy yielded synergistic efficacy. Our findings establish Mettl8 as a pivotal regulator of TPEX fate and a promising therapeutic target for enhancing immunotherapy.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Targeting Mettl8-Tcf1 axis promotes CD8+ TPEX differentiation and antitumor immunity. · full record | OpenQuestion